Oxyntomodulin: Actions and role in diabetes
•Oxyntomodulin is co-secreted with GLP-1 and glicentin from the intestinal L-cells.•Oxyntomodulin has glucagon-like bioactivity and also activates the GLP-1R.•Oxyntomodulin is as such a naturally occurring glucagon and GLP-1 receptor co-agonist. Oxyntomodulin is a product of the glucagon precursor,...
Gespeichert in:
| Veröffentlicht in: | Peptides (New York, N.Y. : 1980) N.Y. : 1980), 2018-02, Vol.100, p.48-53 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 53 |
|---|---|
| container_issue | |
| container_start_page | 48 |
| container_title | Peptides (New York, N.Y. : 1980) |
| container_volume | 100 |
| creator | Holst, Jens J. Albrechtsen, Nicolai J.Wewer Gabe, Maria Buur Nordskov Rosenkilde, Mette Marie |
| description | •Oxyntomodulin is co-secreted with GLP-1 and glicentin from the intestinal L-cells.•Oxyntomodulin has glucagon-like bioactivity and also activates the GLP-1R.•Oxyntomodulin is as such a naturally occurring glucagon and GLP-1 receptor co-agonist.
Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33–69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases. |
| doi_str_mv | 10.1016/j.peptides.2017.09.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1999678832</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0196978117303017</els_id><sourcerecordid>1999678832</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-d3e5269fda30d9e8ed582f396afb4317a32f38c12f511e291ff0f8e8a1e757be3</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMotlb_QtmjILtmkv1IPFmKX1DoRc8hm0wgZb_c7Ir9926p9eppGHjeeZmHkCXQBCjk97ukw27wFkPCKBQJlQkFcUbmIAoeZ5DLczKnIPNYFgJm5CqEHaU0TaW4JDMmU2CCw5zcbb_3zdDWrR0r3zxEKzP4tgmRbmzUtxVGvoms1yUOGK7JhdNVwJvfuSAfz0_v69d4s315W682sUl5OsSWY8Zy6azm1EoUaDPBHJe5dmXKodB82oQB5jIAZBKco06g0IBFVpTIF-T2eLfr288Rw6BqHwxWlW6wHYMCKWVeCMHZhOZH1PRtCD061fW-1v1eAVUHUWqnTqLUQZSiUk2ipuDyt2Msa7R_sZOZCXg8Ajh9-uWxV8F4bAxa36MZlG39fx0_b9h8lA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1999678832</pqid></control><display><type>article</type><title>Oxyntomodulin: Actions and role in diabetes</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Holst, Jens J. ; Albrechtsen, Nicolai J.Wewer ; Gabe, Maria Buur Nordskov ; Rosenkilde, Mette Marie</creator><creatorcontrib>Holst, Jens J. ; Albrechtsen, Nicolai J.Wewer ; Gabe, Maria Buur Nordskov ; Rosenkilde, Mette Marie</creatorcontrib><description>•Oxyntomodulin is co-secreted with GLP-1 and glicentin from the intestinal L-cells.•Oxyntomodulin has glucagon-like bioactivity and also activates the GLP-1R.•Oxyntomodulin is as such a naturally occurring glucagon and GLP-1 receptor co-agonist.
Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33–69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases.</description><identifier>ISSN: 0196-9781</identifier><identifier>EISSN: 1873-5169</identifier><identifier>DOI: 10.1016/j.peptides.2017.09.018</identifier><identifier>PMID: 29412831</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Amino Acids - genetics ; Diabetes ; Diabetes Mellitus - drug therapy ; Diabetes Mellitus - genetics ; Diabetes Mellitus - metabolism ; Glucagon - chemistry ; Glucagon - metabolism ; Glucagon - therapeutic use ; Humans ; Obesity - drug therapy ; Obesity - genetics ; Obesity - metabolism ; Oxyntomodulin ; Oxyntomodulin - chemistry ; Oxyntomodulin - metabolism ; Oxyntomodulin - therapeutic use ; Proglucagon ; Proglucagon - chemistry ; Proglucagon - metabolism ; Proglucagon - therapeutic use ; Proprotein Convertases - chemistry ; Proprotein Convertases - metabolism</subject><ispartof>Peptides (New York, N.Y. : 1980), 2018-02, Vol.100, p.48-53</ispartof><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-d3e5269fda30d9e8ed582f396afb4317a32f38c12f511e291ff0f8e8a1e757be3</citedby><cites>FETCH-LOGICAL-c434t-d3e5269fda30d9e8ed582f396afb4317a32f38c12f511e291ff0f8e8a1e757be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0196978117303017$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29412831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holst, Jens J.</creatorcontrib><creatorcontrib>Albrechtsen, Nicolai J.Wewer</creatorcontrib><creatorcontrib>Gabe, Maria Buur Nordskov</creatorcontrib><creatorcontrib>Rosenkilde, Mette Marie</creatorcontrib><title>Oxyntomodulin: Actions and role in diabetes</title><title>Peptides (New York, N.Y. : 1980)</title><addtitle>Peptides</addtitle><description>•Oxyntomodulin is co-secreted with GLP-1 and glicentin from the intestinal L-cells.•Oxyntomodulin has glucagon-like bioactivity and also activates the GLP-1R.•Oxyntomodulin is as such a naturally occurring glucagon and GLP-1 receptor co-agonist.
Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33–69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases.</description><subject>Amino Acids - genetics</subject><subject>Diabetes</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Diabetes Mellitus - genetics</subject><subject>Diabetes Mellitus - metabolism</subject><subject>Glucagon - chemistry</subject><subject>Glucagon - metabolism</subject><subject>Glucagon - therapeutic use</subject><subject>Humans</subject><subject>Obesity - drug therapy</subject><subject>Obesity - genetics</subject><subject>Obesity - metabolism</subject><subject>Oxyntomodulin</subject><subject>Oxyntomodulin - chemistry</subject><subject>Oxyntomodulin - metabolism</subject><subject>Oxyntomodulin - therapeutic use</subject><subject>Proglucagon</subject><subject>Proglucagon - chemistry</subject><subject>Proglucagon - metabolism</subject><subject>Proglucagon - therapeutic use</subject><subject>Proprotein Convertases - chemistry</subject><subject>Proprotein Convertases - metabolism</subject><issn>0196-9781</issn><issn>1873-5169</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LAzEQhoMotlb_QtmjILtmkv1IPFmKX1DoRc8hm0wgZb_c7Ir9926p9eppGHjeeZmHkCXQBCjk97ukw27wFkPCKBQJlQkFcUbmIAoeZ5DLczKnIPNYFgJm5CqEHaU0TaW4JDMmU2CCw5zcbb_3zdDWrR0r3zxEKzP4tgmRbmzUtxVGvoms1yUOGK7JhdNVwJvfuSAfz0_v69d4s315W682sUl5OsSWY8Zy6azm1EoUaDPBHJe5dmXKodB82oQB5jIAZBKco06g0IBFVpTIF-T2eLfr288Rw6BqHwxWlW6wHYMCKWVeCMHZhOZH1PRtCD061fW-1v1eAVUHUWqnTqLUQZSiUk2ipuDyt2Msa7R_sZOZCXg8Ajh9-uWxV8F4bAxa36MZlG39fx0_b9h8lA</recordid><startdate>201802</startdate><enddate>201802</enddate><creator>Holst, Jens J.</creator><creator>Albrechtsen, Nicolai J.Wewer</creator><creator>Gabe, Maria Buur Nordskov</creator><creator>Rosenkilde, Mette Marie</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201802</creationdate><title>Oxyntomodulin: Actions and role in diabetes</title><author>Holst, Jens J. ; Albrechtsen, Nicolai J.Wewer ; Gabe, Maria Buur Nordskov ; Rosenkilde, Mette Marie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-d3e5269fda30d9e8ed582f396afb4317a32f38c12f511e291ff0f8e8a1e757be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Amino Acids - genetics</topic><topic>Diabetes</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Diabetes Mellitus - genetics</topic><topic>Diabetes Mellitus - metabolism</topic><topic>Glucagon - chemistry</topic><topic>Glucagon - metabolism</topic><topic>Glucagon - therapeutic use</topic><topic>Humans</topic><topic>Obesity - drug therapy</topic><topic>Obesity - genetics</topic><topic>Obesity - metabolism</topic><topic>Oxyntomodulin</topic><topic>Oxyntomodulin - chemistry</topic><topic>Oxyntomodulin - metabolism</topic><topic>Oxyntomodulin - therapeutic use</topic><topic>Proglucagon</topic><topic>Proglucagon - chemistry</topic><topic>Proglucagon - metabolism</topic><topic>Proglucagon - therapeutic use</topic><topic>Proprotein Convertases - chemistry</topic><topic>Proprotein Convertases - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holst, Jens J.</creatorcontrib><creatorcontrib>Albrechtsen, Nicolai J.Wewer</creatorcontrib><creatorcontrib>Gabe, Maria Buur Nordskov</creatorcontrib><creatorcontrib>Rosenkilde, Mette Marie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Peptides (New York, N.Y. : 1980)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holst, Jens J.</au><au>Albrechtsen, Nicolai J.Wewer</au><au>Gabe, Maria Buur Nordskov</au><au>Rosenkilde, Mette Marie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oxyntomodulin: Actions and role in diabetes</atitle><jtitle>Peptides (New York, N.Y. : 1980)</jtitle><addtitle>Peptides</addtitle><date>2018-02</date><risdate>2018</risdate><volume>100</volume><spage>48</spage><epage>53</epage><pages>48-53</pages><issn>0196-9781</issn><eissn>1873-5169</eissn><abstract>•Oxyntomodulin is co-secreted with GLP-1 and glicentin from the intestinal L-cells.•Oxyntomodulin has glucagon-like bioactivity and also activates the GLP-1R.•Oxyntomodulin is as such a naturally occurring glucagon and GLP-1 receptor co-agonist.
Oxyntomodulin is a product of the glucagon precursor, proglucagon, produced and released from the endocrine L-cells of the gut after enzymatic processing by the precursor prohormone convertase 1/3. It corresponds to the proglucagon sequence 33–69 and thus contains the entire glucagon sequence plus a C-terminal octapeptide, comprising in total 37 amino acids. As might have been expected, it has glucagon-like bioactivity, but also and more surprisingly also activates the receptor for GLP-1. This has given the molecule an interesting status as a glucagon-GLP-1 co-agonist, which is currently attracting considerable interest for its potential in the treatment of diabetes and obesity. Here, we provide an update on oxyntomodulin with a focus on its potential role in metabolic diseases.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29412831</pmid><doi>10.1016/j.peptides.2017.09.018</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0196-9781 |
| ispartof | Peptides (New York, N.Y. : 1980), 2018-02, Vol.100, p.48-53 |
| issn | 0196-9781 1873-5169 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1999678832 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Amino Acids - genetics Diabetes Diabetes Mellitus - drug therapy Diabetes Mellitus - genetics Diabetes Mellitus - metabolism Glucagon - chemistry Glucagon - metabolism Glucagon - therapeutic use Humans Obesity - drug therapy Obesity - genetics Obesity - metabolism Oxyntomodulin Oxyntomodulin - chemistry Oxyntomodulin - metabolism Oxyntomodulin - therapeutic use Proglucagon Proglucagon - chemistry Proglucagon - metabolism Proglucagon - therapeutic use Proprotein Convertases - chemistry Proprotein Convertases - metabolism |
| title | Oxyntomodulin: Actions and role in diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T15%3A06%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oxyntomodulin:%20Actions%20and%20role%20in%20diabetes&rft.jtitle=Peptides%20(New%20York,%20N.Y.%20:%201980)&rft.au=Holst,%20Jens%20J.&rft.date=2018-02&rft.volume=100&rft.spage=48&rft.epage=53&rft.pages=48-53&rft.issn=0196-9781&rft.eissn=1873-5169&rft_id=info:doi/10.1016/j.peptides.2017.09.018&rft_dat=%3Cproquest_cross%3E1999678832%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1999678832&rft_id=info:pmid/29412831&rft_els_id=S0196978117303017&rfr_iscdi=true |